| pubmed-article:2651003 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C1551338 | lld:lifeskim |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C0025815 | lld:lifeskim |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C0242966 | lld:lifeskim |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C1719672 | lld:lifeskim |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:2651003 | lifeskim:mentions | umls-concept:C2349099 | lld:lifeskim |
| pubmed-article:2651003 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2651003 | pubmed:dateCreated | 1989-6-7 | lld:pubmed |
| pubmed-article:2651003 | pubmed:abstractText | The sepsis syndrome represents a systemic response to infection and is defined as hypothermia (temperature less than 96 degrees F) or hyperthermia (greater than 101 degrees F), tachycardia (greater than 90 beat/min), tachypnea (greater than 20 breath/min), clinical evidence of an infection site and with at least one end-organ demonstrating inadequate perfusion or dysfunction expressed as poor or altered cerebral function, hypoxemia (PaO2 less than 75 torr), elevated plasma lactate, or oliguria (urine output less than 30 ml/h or 0.5 ml/kg body weight.h without corrective therapy). One hundred ninety-one patients with the sepsis syndrome were evaluated prospectively and comprised the placebo group of a multicenter trial of methylprednisolone in sepsis syndrome and septic shock. Forty-five percent of the patients were found to be bacteremic. Thirty-six percent of the patients were in septic shock (sepsis syndrome plus a systolic BP less than 90 mm Hg or a decrease from baseline in systolic BP greater than 40 mm Hg) on study entry. An additional 23% of the patients developed shock after admission with 70% doing so within 24 h of study entry. Shock reversal occurred with a 73% frequency. Twenty-five percent of the patients developed the adult respiratory distress syndrome (ARDS). Mortality for the patients with sepsis syndrome who did not develop shock was 13%. Mortality for the groups of patients with shock on admission and shock postadmission was 27.5% and 43.2%, respectively. Forty-seven percent of the bacteremic patients developed shock after study admission compared to 29.6% of the nonbacteremic patients (p less than .05).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2651003 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2651003 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2651003 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2651003 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2651003 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2651003 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2651003 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2651003 | pubmed:month | May | lld:pubmed |
| pubmed-article:2651003 | pubmed:issn | 0090-3493 | lld:pubmed |
| pubmed-article:2651003 | pubmed:author | pubmed-author:BoneR CRC | lld:pubmed |
| pubmed-article:2651003 | pubmed:author | pubmed-author:SlotmanG JGJ | lld:pubmed |
| pubmed-article:2651003 | pubmed:author | pubmed-author:FisherC JCJJr | lld:pubmed |
| pubmed-article:2651003 | pubmed:author | pubmed-author:ClemmerT PTP | lld:pubmed |
| pubmed-article:2651003 | pubmed:author | pubmed-author:BalkR ARA | lld:pubmed |
| pubmed-article:2651003 | pubmed:author | pubmed-author:MetzC ACA | lld:pubmed |
| pubmed-article:2651003 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2651003 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:2651003 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2651003 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2651003 | pubmed:pagination | 389-93 | lld:pubmed |
| pubmed-article:2651003 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:meshHeading | pubmed-meshheading:2651003-... | lld:pubmed |
| pubmed-article:2651003 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2651003 | pubmed:articleTitle | Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. | lld:pubmed |
| pubmed-article:2651003 | pubmed:affiliation | Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612. | lld:pubmed |
| pubmed-article:2651003 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2651003 | lld:pubmed |
